We are live on
!
Find out more
ACM
Aquilo Capital Management Portfolio holdings
AUM
$55.8M
1-Year Est. Return
41.76%
This Fund
S&P 500
This Quarter
Est. Return
+48.78%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$226M
AUM Growth
+$19.3M
(+9.3%)
Cap. Flow
-$39M
Cap. Flow
% of AUM
-17.25%
Top 10 Holdings %
Top 10 Hldgs %
95.5%
Holding
17
New
3
Increased
3
Reduced
5
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProQR Therapeutics
PRQR
|
+$7.27M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
+$2.26M |
| 3 |
SYBX
Synlogic
SYBX
|
+$514K |
| 4 |
Spero Therapeutics
SPRO
|
+$238K |
| 5 |
MRUS
Merus
MRUS
|
+$136K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CytomX Therapeutics
CTMX
|
+$6.25M |
| 2 |
argenx
ARGX
|
+$4.4M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$3.47M |
| 4 |
uniQure
QURE
|
+$1.97M |
| 5 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$1.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares Biotechnology ETF
IBB
$9.71B
| $55.9M | 24.74% |
+500,000
| New | +$54.8M |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $45.3M | 20.04% |
500,000
-1,000,000
| -67% | -$85.1M |
|
|
MRUS
3
DELISTED
Merus
MRUS
| $22M | 9.75% |
1,491,497
+10,642
| +0.7% | +$136K |
|
|
4
uniQure
QURE
$3.22B
| $21.7M | 9.63% |
364,596
-44,133
| -11% | -$1.97M |
|
5
Arrowhead Research
ARWR
$12.4B
| $18M | 7.98% |
982,455
-82,473
| -8% | -$1.36M |
|
|
6
Spero Therapeutics
SPRO
$73M
| $13.5M | 5.98% |
1,054,356
+22,409
| +2% | +$238K |
|
7
Fate Therapeutics
FATE
$326M
| $12.2M | 5.42% |
697,096
| – | – |
|
|
SYBX
8
DELISTED
Synlogic
SYBX
| $10.6M | 4.69% |
93,134
+4,189
| +5% | +$514K |
|
9
Xenon Pharmaceuticals
XENE
$6.12B
| $9.67M | 4.28% |
951,527
| – | – |
|
|
10
ProQR Therapeutics
PRQR
$265M
| $6.75M | 2.99% |
+486,698
| New | +$7.27M |
|
|
PVLA
11
Palvella Therapeutics
PVLA
$2.27B
| $4.06M | 1.8% |
15,135
| – | – |
|
|
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
| $2.57M | 1.14% |
21,840
-14,080
| -39% | -$1.42M |
|
|
BPMC
13
DELISTED
Blueprint Medicines
BPMC
| $2.45M | 1.08% |
+30,618
| New | +$2.26M |
|
|
14
CytomX Therapeutics
CTMX
$754M
| $1.09M | 0.48% |
101,767
-422,996
| -81% | -$6.25M |
|
|
15
argenx
ARGX
$54.1B
| – | – |
-45,806
| Closed | -$4.4M |
|
|
MOR
16
DELISTED
MorphoSys AG American Depositary Shares
MOR
| – | – |
-11,787
| Closed | -$298K |
|
|
LOXO
17
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-24,750
| Closed | -$3.47M |
|
Similar funds
VCM
YEPV
HWP
GIS
AA
PGIM
RGMC
PAM
Aquilo Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Aquilo Capital Management held 17 positions worth $226M, up 9.3% from $207M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Aquilo Capital Management withdrew a net $39M in Q1 2019, closing 3 positions and reducing 5 holdings. Its most notable exit was argenx, an estimated $4.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 48% a quarter earlier.
Against the trend, Aquilo Capital Management opened a new position in ProQR Therapeutics worth $6.75M.
- Aquilo Capital Management's largest Q1 2019 buy was ProQR Therapeutics: 486,698 shares worth $6.75M.
- Aquilo Capital Management added most to Synlogic in Q1 2019, an estimated $514K increase.
- Aquilo Capital Management's biggest Q1 2019 reduction was CytomX Therapeutics, cutting an estimated $6.25M.
- Aquilo Capital Management fully exited argenx in Q1 2019, selling an estimated $4.4M.
- Aquilo Capital Management's ten largest holdings make up 95% of its $226M portfolio in Q1 2019.
- Aquilo Capital Management opened 3 new positions and closed 3 in Q1 2019.
- Aquilo Capital Management's portfolio value rose 9.3% quarter-over-quarter to $226M.
Based on Aquilo Capital Management's 13F filing for Q1 2019, filed 15 May 2019.